fda warning letters glp-1 compounding october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA issues 30 warning letters

Keep the vial tightly sealed when not in use

Far From "Just a Poke": Common Painful Needle Procedures and the Development of Needle Fear

Im not sure if thats the drug or the trial sites encouraging patients, but its great to see this

As these dangerous molecules are eliminated, glutathione contributes to skin that looks youthful

Considering the many limitations of intravenous glutathione, it is prudent that dermatologists refrain from administering such injections for skin lightening until further trials and high quality studies establish a favourable benefit versus risk ratio that justify its use [Box 7]

6e,f), the oxidative product of 5-methylcytosine (5mC) catalyzed by TETs